Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL3901152 | 0.79 | KDM4E (0.92) | KDM4EALDH1A1P4HTMMEN1KMT2A | |
| SCHEMBL157288 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1P4HTMMEN1KMT2A | |
| SCHEMBL29539391 | 0.77 | ALDH1A1 (0.67) | KDM4EALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL3901156 | 0.77 | KDM4E (0.96) | KDM4EALDH1A1P4HTMMEN1KMT2A | |
| SCHEMBL27660665 | 0.77 | ALDH1A1 (0.67) | KDM4EALDH1A1P4HTMRAB9ANPC1 | |
| SCHEMBL787729 | 0.77 | ALDH1A1 (0.67) | KDM4EALDH1A1P4HTMRAB9ANPC1 | |
| SCHEMBL157129 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1MEN1 | |
| Hydrochloric Acid SCHEMBL5934153 | 0.77 | KDM4E (0.96) | KDM4EALDH1A1P4HTMMEN1KMT2A | |
| SCHEMBL471438 | 0.77 | ALDH1A1 (0.67) | KDM4EALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL16070636 | 0.75 | ALDH1A1 (0.70) | KDM4EALDH1A1P4HTMRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116722143-A | Application of lithium carboxylate with N-containing six-membered ring structure and anode of anode-free lithium metal battery | 哈尔滨工业大学 | 2023-09-08 | — | — | CN | claimed |
| CN-116722143-B | Application of lithium carboxylate with N-containing six-membered ring structure and anode of anode-free lithium metal battery | 哈尔滨工业大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-116722143-B | Application of lithium carboxylate with N-containing six-membered ring structure and anode of anode-free lithium metal battery | 哈尔滨工业大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-116722143-A | Application of lithium carboxylate with N-containing six-membered ring structure and anode of anode-free lithium metal battery | 哈尔滨工业大学 | 2023-09-08 | — | — | CN | disclosed |
| CN-116722143-A | Application of lithium carboxylate with N-containing six-membered ring structure and anode of anode-free lithium metal battery | 哈尔滨工业大学 | 2023-09-08 | — | — | CN | disclosed |
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1869016-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006095159-A1 | (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | KDM4E 734/4885ALDH1A1 466/4885CA1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.